Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

Zhu, Song-Xin; Wang, Yuming; Tang, Jun; Cao, Min

doi:10.3389/fimmu.2022.1074477

Cited by 27 publications

(11 citation statements)

References 259 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 E). Since both chemotherapy and radiotherapy can affect the tumor immune microenvironment, TIDE and TMB are considered markers of the tumor immune microenvironment in multiple cancers [ [25] , [26] , [27] , [28] ]. In this study, LUM had a positive correlation with TIDE in TCGA-CESC, patients with high LUM had higher TIDE scores than patients with low LUM ( p < 0.001), and the proportion of patients with true response to CCRT in the high-LUM group was also higher than that in the low-LUM group (high LUM: true: 18%, false: 82%; low LUM: true, 41%; false, 59%) ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma

Hu¹,

Xiao²,

Ma³

et al. 2023

Heliyon

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma

Hu¹,

Xiao²,

Ma³

et al. 2023

Heliyon

View full text Add to dashboard Cite

“…Radiation therapy not only kills tumor cells, but also kills other normal tissues, cells, and components of the human body. Different individuals exhibit different response effects to radiation exposure, thereby triggering corresponding clinical manifestations, radiodermatitis is one of them [13].As the dose increases, skin erosion and ulcers appear at the irradiated area. This type of radiation dermatitis is generally acute skin injury, after stopping the irradiation, the skin erosion and ulcers gradually heal, generally speaking, there will be no permanent skin damage or functional impairment left behind.…”

Section: Discussionmentioning

confidence: 99%

Adverse reactions of postoperative superficial radiotherapy for non-melanoma skin malignant tumors

Song,

Zhou,

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Surgical excision is the preferred treatment option for the vast majority of non-melanoma skin malignant tumors, and postoperative adjuvant radiotherapy can effectively kill residual tumor cells, thereby reducing the tumor recurrence rate. A small number of patients have varying degrees of adverse reactions after receiving radiation therapy. Objective To evaluate the adverse reactions of adjuvant radiotherapy after surgical resection for different types of non-melanoma skin malignant tumors, and provide reference for postoperative adjuvant radiotherapy for non-melanoma skin malignant tumors. Methods To collect basic data of hospitalized patients with non-melanoma malignant skin tumors in the dermatology department of our hospital who underwent surgical resection combined with superficial radiotherapy from June 2022 to June 2023, and conduct a retrospective analysis of the total dose, treatment period, and major adverse reactions of the patients receiving radiation therapy and summarize some information with reference value Results The main adverse reaction of postoperative superficial radiotherapy for non-melanoma malignant skin tumors is radiodermatitis. Among the 21 patients included, a total of 7 individuals developed radiodermatitis. Six patients with tumors located in areas rich in subcutaneous fat developed radiodermatitis, while one patient with tumors located in areas weak in subcutaneous fat developed radiodermatitis. Among them, 9 patients completed radiation therapy in one stage, 5 patients developed radiodermatitis; 12 patients completed radiation therapy in two stages, and 2 patients developed radiodermatitis. Conclusions Different human bodies have different sensitivities and tolerances to radiotherapy, and the probability of developing radiodermatitis varies. There is no significant correlation between the occurrence of radiodermatitis and the total radiation dose. Areas with abundant subcutaneous fat (such as abdomen, back, buttocks and proximal limbs) are more prone to radiodermatitis compared to areas with thin subcutaneous fat (such as scalp, facial, lip, ear, nasal, vulva, scrotum and toe). Dividing the total treatment cycle can effectively reduce the incidence of radiodermatitis.

show abstract

“…This suggests a possible systemic immune-stimulatory effect that might not necessitate an overlap of the treatment fields. In fact, given the radiosensitivity of immune cells and the acute effect of RT on immune cell death [ 24 , 25 ], non-superimposed treatment may potentially lead to a more robust immunogenicity. Our understanding of the biological underpinning of the abscopal effect is limited.…”

Section: Discussionmentioning

confidence: 99%

Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma

Tam,

Ladbury,

Kassardjian

et al. 2024

Cancers

View full text Add to dashboard Cite

Talimogene laherparepvec (TVEC) is a genetically modified oncolytic herpes simplex virus (HSV-1) that is used for the intralesional treatment of advanced or metastatic melanoma. Given that TVEC produces the granulocyte–macrophage colony-stimulating factor (GM-CSF), recent reports have suggested that radiation treatment (RT) given in conjunction with TVEC may provide synergistic immune activation at the site, and possibly systemically. However, studies on combining RT with TVEC remain limited. We conducted a retrospective review of melanoma patients from a single cancer center who received TVEC and RT in the same region of the body and compared them to patients who received TVEC with RT at another site (other than the site of TVEC injection). Between January 2015 and September 2022, we identified twenty patients who were treated with TVEC and RT; fourteen patients received TVEC and RT in the same region, and six had treatments in separate regions. Regions were determined at the time of analysis and were based on anatomic sites (such as arm, leg, torso, etc.). Kaplan–Meier analysis of progression-free survival (PFS), analyses of time to distant metastasis (DM), overall survival (OS), and locoregional control (LRC), and the corresponding log-rank test were performed. With a median follow-up of 10.5 months [mos] (range 1.0–58.7 mos), we found an improvement in PFS with TVEC and RT in the same region compared to different regions, which were 6.4 mos (95% CI, 2.4–NR mos) and 2.8 mos (95% CI, 0.7–4.4 mos), respectively; p = 0.005. There was also a significant improvement in DM when TVEC and RT were used in the same region compared to different regions: 13.8 mos (95% CI, 4.6–NR mos) and 2.8 mos (95% CI, 0.7–4.4 mos), respectively (p = 0.001). However, we found no difference in overall survival (OS) between patients who had TVEC and RT in the same region (19.0 mos, 95% confidence interval [CI], 4.1–not reached [NR] mos) and those who received treatments in different regions (18.5 mos, 95% CI, 1.0–NR mos); p = 0.366. There was no statistically significant improvement in locoregional control (LRC) in patients who had TVEC and RT in the same region was 26.0 mos (95% CI, 6.4–26.0 mos) compared to patients who received TVEC and RT in different regions (4.4 mos) (95% CI, 0.7–NR mos) (p = 0.115). No grade 3 or higher toxicities were documented in either group. Overall, there were improvements in PFS and DM when TVEC and RT were delivered to the same region of the body compared to when they were used in different regions. However, we did not find a significant difference in locoregional recurrence or OS. Future studies are needed to assess the sequence and timing of combining RT and TVEC to potentially enhance the immune response both locally and distantly.

show abstract

Radiotherapy induced immunogenic cell death by remodeling tumor immune microenvironment

Cited by 27 publications

References 259 publications

Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma

Lumican is a potential predictor on the efficacy of concurrent chemoradiotherapy in cervical squamous cell carcinoma

Adverse reactions of postoperative superficial radiotherapy for non-melanoma skin malignant tumors

Combined Regional Approach of Talimogene laherparepvec and Radiotherapy in the Treatment of Advanced Melanoma

Contact Info

Product

Resources

About